NASDAQ:MGTX

MeiraGTx Stock Forecast, Price & News

$15.28

-0.46 (-2.92 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$15.17

Now: $15.28▼

$15.84

50-Day Range

$12.40

MA: $15.39▼

$17.60

52-Week Range

$8.82

Now: $15.28▼

$21.77

Volume98,146 shs

Average Volume97,704 shs

Market Capitalization$586.94 million

P/E RatioN/A

Dividend YieldN/A

Beta1.33

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.

MarketRank^™

Overall MarketRank^™

1.45 out of 5 stars

Medical Sector

485th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

63rd out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
MeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $33.00, MeiraGTx has a forecasted upside of 116.0% from its current price of $15.28.
Amount of Analyst Coverage
MeiraGTx has received no research coverage in the past 90 days.

2.9 Community Rank

Outperform Votes
MeiraGTx has received 176 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MeiraGTx has received 131 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MeiraGTx has received 57.33% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote “Outperform” if you believe MGTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MeiraGTx does not currently pay a dividend.
Dividend Growth
MeiraGTx does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,434,140.00 in company stock.
Percentage Held by Insiders
Only 16.50% of the stock of MeiraGTx is held by insiders.
Percentage Held by Institutions
56.40% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for MeiraGTx are expected to decrease in the coming year, from ($1.70) to ($2.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MeiraGTx is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MeiraGTx is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MeiraGTx has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MGTX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.meiragtx.com

Phone646-860-7985

Employees206

Debt

Debt-to-Equity Ratio0.10

Current Ratio4.67

Quick Ratio4.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$13.29 million

Price / Sales44.16

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.22 per share

Price / Book2.93

Profitability

EPS (Most Recent Fiscal Year)($1.65)

Net Income$-54,750,000.00

Net Margins-283.20%

Return on Equity-29.14%

Return on Assets-17.49%

Miscellaneous

Outstanding Shares38,412,000

Market Cap$586.94 million

Next Earnings Date3/10/2021 (Estimated)

OptionableNot Optionable

$15.28

-0.46 (-2.92 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.

MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

How has MeiraGTx's stock been impacted by COVID-19?

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MGTX shares have increased by 8.4% and is now trading at $15.28.
View which stocks have been most impacted by COVID-19.

Is MeiraGTx a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MeiraGTx stock.
View analyst ratings for MeiraGTx or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MeiraGTx?

Wall Street analysts have given MeiraGTx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MeiraGTx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as MeiraGTx's CEO?

1,448 employees have rated MeiraGTx CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among MeiraGTx's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for MeiraGTx.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.53. The firm had revenue of $5.09 million for the quarter. MeiraGTx had a negative return on equity of 29.14% and a negative net margin of 283.20%.
View MeiraGTx's earnings history.

What price target have analysts set for MGTX?

4 brokerages have issued 1-year target prices for MeiraGTx's shares. Their forecasts range from $20.00 to $45.00. On average, they anticipate MeiraGTx's stock price to reach $33.00 in the next year. This suggests a possible upside of 116.0% from the stock's current price.
View analysts' price targets for MeiraGTx or view Wall Street analyst' top-rated stocks.

Who are some of MeiraGTx's key competitors?

Some companies that are related to MeiraGTx include Bavarian Nordic A/S (BVNRY), Sangamo Therapeutics (SGMO), Replimune Group (REPL), NantKwest (NK), Vericel (VCEL), Scholar Rock (SRRK), Translate Bio (TBIO), BioCryst Pharmaceuticals (BCRX), REGENXBIO (RGNX), C4 Therapeutics (CCCC), Forma Therapeutics (FMTX), Atara Biotherapeutics (ATRA), Krystal Biotech (KRYS), Cellectis (CLLS) and Inhibrx (INBX).
View all of MGTX's competitors.

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the following people:

Dr. Alexandria Forbes, CEO, Pres & Director (Age 56, Pay $8.48M)
Mr. Richard Brian Giroux B.A., COO & CFO (Age 47, Pay $7.47M)
Mr. Robert Wollin J.D., Gen. Counsel & Sec.
Dr. Stuart Naylor Ph.D., Chief Devel. Officer (Age 58)
Prof. Gregory A. Petsko D.Phil., Ph.D., Chief Scientist & Chairman of Scientific Advisory Board
Ms. Christine E. Sheehy, Sr. VP of Global Integration
Mr. Joel P. Brooks, Sr. VP of Fin. (Age 62)
Mr. Tim Randall, Sr. VP of Risk & Internal Controls
Dr. Alastair Leighton, Sr. VP of Manufacturing & Supply Chain
Dr. Robert K. Zeldin M.D., Chief Medical Officer (Age 58)

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.17%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Stuart Naylor and Thomas E Shenk.
View institutional ownership trends for MeiraGTx.

Which major investors are buying MeiraGTx stock?

MGTX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive, and Nicole Seligman.
View insider buying and selling activity for MeiraGTx or or view top insider-buying stocks.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $15.28.

How big of a company is MeiraGTx?

MeiraGTx has a market capitalization of $586.94 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. MeiraGTx employs 206 workers across the globe.

What is MeiraGTx's official website?

The official website for MeiraGTx is www.meiragtx.com.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here